Furthermore, the increased expression of PD-L1 in both tumor and immune cells [17,18] suggested that this aggressive breast cancer phenotype may be responsive to immune checkpoint inhibitor (ICI) therapy. The gene discussed is CD274; the disease is breast carcinoma.